Cetuximab  (Synonyms: 西妥昔单抗; C225)

Cetuximab (C225) is a human IgG1 monoclonal antibody that inhibits epidermal growth factor receptor (EGFR), with a K_d of 0.201 nM for EGFR by SPR. Cetuximab has potent antitumor activity^[1].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Chimeric

Cetuximab (C225) 是一种抑制表皮生长因子受体 (EGFR) 的单克隆抗体，SPR 对可溶性 EGFR 的 K_d 为 0.201 nM。通过 ELISA 检测，Cetuximab 在固定 A431 细胞中对 EGFR 的 K_d 也为 0.147 nM^[1]。
Cetuximab (C225；30 nM) 在处理 8 天后时间依赖性地抑制 SCC-1、SCC-11B、SCC-38 和 SCC-13Y 细胞的增殖。Cetuximab (30 nM) 导致 G₀/G₁ 停滞，诱导细胞凋亡，并减少 Rb、p27^KIP1、Bcl-2 和 Bax 在 SCC-13Y 细胞中的表达。Cetuximab (30 nM) 还可增强放射敏感性并增加 SCC-13Y 细胞中放射诱导的细胞凋亡^[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cetuximab (1 毫克/注射) 对肿瘤体积有影响，但对 UT-SCC-14 异种移植物的影响更为明显。在 UT-SCC-14 异种移植物中，Cetuximab 可显著降低 EGFR、pEGFR 和 Ki67 的表达。Cetuximab 显著降低 MCT1 和 GLUT1 细胞中的表达，但差异在 UT-SCC-14 异种移植物中更为明显^[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

205923-56-4

液体

Colorless to light yellow

西妥昔单抗

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Cetuximab has a significant ADCC effect on A431 cells in a dose-dependent manner.The EC₅₀ for this effect is 43.50 and 39.11 ng/mL.

• [1]. Goldstein NI, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995 Nov;1(11):1311-8.  [Content Brief]

  [2]. Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Jul 29.  [Content Brief]

  [3]. Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59(8):1935-40.  [Content Brief]